Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.

Vogl, Thomas J.; Kümmel, Sherko; Hammerstingl, Renate; Schellenbeck, M; Schumacher, G; Balzer, Thomas; Schwarz, W.; Müller, P.; Bechstein, Wolf O.; Mack, Martin G.; Söllner, O.; Félix, R.

doi:10.1148/radiology.200.1.8657946

Cited by 445 publications

(315 citation statements)

References 0 publications

Supporting

Mentioning

290

Contrasting

Unclassified

Order By: Relevance

“…Gadoxetic acid can effectively be used in dynamic and liver-specific static MRI with accurate delineation, classification, and characterization of liver tumors, in which excellent sensitivity and characterization for hepatocellular lesions are provided (10,12,14,(16)(17)(18)(19). The diagnosis of early HCC is one of the potential indication (20,21). Decreased signal intensity on hepatocyte-phase is strongly correlated with carcinogenesis of HCC (22).…”

Section: Discussionmentioning

confidence: 99%

Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease

Motosugi

Ichikawa

Sano

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose: To elucidate the natural history of hypovascular nodules that appear hypointense on hepatocyte-phase gadoxetic acid-enhanced MR images by focusing on hypervascularization over time. Materials and Methods:In this study, 135 hypovascular nodules revealing no gadoxetic acid uptake in 53 patients were examined. All nodules were retrospectively examined using serial follow-up computed tomography (CT) and MRI examinations until hypervascularity was observed on arterial-phase dynamic CT or gadoxetic acid-enhanced MR images, or on CT during hepatic arteriography. Logistic regression analysis was used to investigate the association between hypervascularization and MR findings including a presence of fat assessed by a signal drop on opposed-phase T1-weighted images.Results: Of the 135 nodules, 16 underwent hypervascularization. The size of the nodules and the presence of fat in the nodules were independent indicators of hypervascularization. The 1-year cumulative risk of hypervascularization was 15.6%. This risk was significantly increased in the case of nodules >10 mm (37.6%, P < 0.01) and fatcontaining nodules (26.5%, P < 0.01).Conclusion: Hypovascular nodules that appear hypointense on hepatocyte-phase gadoxetic acid-enhanced MR images may progress to conventional hypervascular hepatocellular carcinoma. Nodules more than 10 mm in diameter and containing fat are at high risk for developing hypervascularization.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease

Motosugi

Ichikawa

Sano

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…In several clinical studies, this contrast agent has been demonstrated to provide differential diagnostic information comparable to nonspecific gadolinium chelates (8,14) and to improve the detection of focal liver lesions due to its highly specific uptake by hepatocytes (20). In addition, Gd-EOB-DTPA allows assessment of arterial perfusion during the vascular phase of dynamic imaging, and may be adapted to the other abdominal organs as well as liver, such as with Gd-DTPA.…”

Section: Discussionmentioning

confidence: 99%

“…These results may indicate that Gd-EOB-DTPA affects the enhancement effect in the arterial phase of various tumors, especially of hypervascular tumors such as hepatocellular carcinoma and renal cell carcinoma (8). Further clinical studies in patients with various tumors are needed to clarify the influence of less enhancement effect of Gd-EOB-DTPA in the arterial phase on MR diagnosis for solid tumors, especially with hypervascularity.…”

Section: Figurementioning

confidence: 98%

Dynamic contrast‐enhanced magnetic resonance imaging of abdominal solid organ and major vessel: Comparison of enhancement effect between Gd‐EOB‐DTPA and Gd‐DTPA

Tamada

Ito

Sone

et al. 2009

Magnetic Resonance Imaging

111

View full text Add to dashboard Cite

Purpose:To evaluate the differences in enhancement of the abdominal solid organ and the major vessel on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) obtained with gadolinium ethoxybenzyldiethylenetriamine pentaacetic acid (Gd-EOB-DTPA: EOB) and gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) in the same patients. Materials and Methods:A total of 13 healthy volunteers underwent repeat assessments of abdominal MR examinations with DCE-MRI using either Gd-DTPA at a dose of 0.1 mmol/kg body weight or EOB at a dose of 0.025 mmol/kg body weight. DCE images were obtained at precontrast injection and in the arterial phase (AP: 25 seconds), portal phase (PP: 70 seconds), and equilibrium phase (EP: 3 minutes). The signal intensities (SIs) of liver at AP, PP, and EP; the SIs of spleen, renal cortex, renal medulla, pancreas, adrenal gland, aorta at AP; and the SIs of portal vein and inferior vena cava (IVC) at PP were defined using region-ofinterest measurements, and were used for calculation of signal intensity ratio (SIR). There was no significant difference in mean SIR of liver at PP between EOB (0.529 Ϯ 0.124) and Gd-DTPA (0.564 Ϯ 0.139). Conversely, the mean SIR of liver at EP was significantly higher with EOB (0.576 Ϯ 0.167) than with Gd-DTPA (0.396 Ϯ 0.093) (P Ͻ 0.001). Results Conclusion:Lower arterial vascular and parenchymal enhancement with Gd-EOB, as compared with Gd-DTPA, may require reassessment of its dose, despite the higher late venous phase liver parenchymal enhancement.

show abstract

“…13,14 The approved package insert dose of gadoxetic acid, 0.025 mmol/kg, yields a quarter of the dose of gadolinium of traditional formulation agents, including gadopentetate dimeglumine, gadoteridol, gadodiamide, gadoversetamide, and gadobenate dimeglumine. 15 This dose was determined based on preclinical studies 16,17 that demonstrated comparable early enhancement of hypervascular tumors between MRI with a 0.025 mmol/kg dose showed comparable early enhancement of hypervascular tumors to gadopentetate dimeglumine 16 A dose of 0.025 mmol/kg was also found to be the minimum effective dose during the hepatobiliary phase for the detection and characterization of lesions. 17 However, the imaging sequences used in these studies (both published in 1996) are no longer routinely used in clinical MR imaging.…”

Section: Introductionmentioning

confidence: 99%

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers

Bannas

Hernando

Rahimi

et al. 2016

MRMS

View full text Add to dashboard Cite

Purpose: We performed a quantitative intraindividual comparison of the performance of 0.025-and 0.05-mmol/kg doses for gadoxetic acid-enhanced liver magnetic resonance (MR) imaging.Materials and Methods: Eleven healthy volunteers underwent liver MR imaging twice, once with a 0.025-and once with a 0.05-mmol/kg dose of gadoxetic acid. MR spectroscopy and 3-dimensional gradient-echo T 1 -weighted images (3D-GRE) were obtained before and 3, 10, and 20 min after injection of the contrast medium to measure T 1 and T 2 values and signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) performance. During the dynamic phase, highly time-resolved 3D-GRE was used to estimate the relative CNR (CNR rel ) of the hepatic artery and portal vein (PV) to the liver. We used paired t-tests to compare the results of different doses.Results: During the hepatobiliary phase, we observed shorter T 1 values and higher SNRs of the liver (P < 0.001) and higher liver-to-PV and liver-to-muscle CNRs (P < 0.002) using 0.05 mmol/kg compared to 0.025 mmol/kg. Increasing the dose to 0.05 mmol/kg yielded a greater T 1 -shortening effect at 10 min delay even compared with 0.025 mmol/kg at 20 min (P < 0.001). During the dynamic phase, the peak CNR rel for the hepatic artery and portal vein were higher using 0.05 mmol/kg (P = 0.007 to 0.035).Conclusion: Use of gadoxetic acid at a dose of 0.05 mmol/kg leads to significantly higher SNR and CNR performance than with 0.025 mmol/kg. Quantitatively, a 10-min delay may be feasible for hepatobiliary-phase imaging when using 0.05 mmol/kg of gadoxetic acid.

show abstract

Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.

Abstract: Gd-EOB-DTPA-enhanced MR imaging enables improved detection of hepatic lesions over Gd-DTPA-enhanced MR imaging while providing comparable differential diagnostic information.

Cited by 445 publications

References 0 publications

Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease

Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease

Dynamic contrast‐enhanced magnetic resonance imaging of abdominal solid organ and major vessel: Comparison of enhancement effect between Gd‐EOB‐DTPA and Gd‐DTPA

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers

Contact Info

Product

Resources

About